Cortiment® – first oral budesonide for the treatment of mild to middle active ulcerative colitis
Milan Lukáš Orcid.org 1
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Ferring Pharmaceuticals. CORTIMENT 9 mg SPC. [online]. Available from: www.medicines.org.uk/emc/medicine/30253.
2. Sandborn WJ, Travis S, Moro L et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143 (5): 1218–1226. doi: 10.1053/j.gastro.2012.08.003.
3. Travis SP, Danese S, Kupcinskas L et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63 (3): 433–441. doi: 10.1136/gutjnl- 2012-304258.
4. Fiorino G, Fries W, De La Rue SA et al. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. Curr Med Chem 2010; 17 (17) : 1851–1857.